Luye Pharma Group Ltd.
LYPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.23 | -1.21 | -0.06 | 0.95 |
| FCF Yield | -16.33% | 3.80% | 2.72% | -8.28% |
| EV / EBITDA | 6.76 | 7.95 | 13.67 | 25.88 |
| Quality | ||||
| ROIC | 3.75% | 3.51% | 4.90% | 3.66% |
| Gross Margin | 66.72% | 68.44% | 69.22% | 65.32% |
| Cash Conversion Ratio | 0.20 | 2.28 | 2.47 | -2.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.44% | 5.71% | 2.59% | -6.48% |
| Free Cash Flow Growth | -458.12% | -12.22% | 136.06% | -179.43% |
| Safety | ||||
| Net Debt / EBITDA | 2.46 | 2.50 | 3.74 | 7.78 |
| Interest Coverage | 2.30 | 1.52 | 2.58 | 0.97 |
| Efficiency | ||||
| Inventory Turnover | 2.21 | 2.34 | 2.38 | 2.42 |
| Cash Conversion Cycle | 299.25 | 165.17 | 151.07 | 159.40 |